The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Rejeski, Kai; Hansen, Doris K.; Bansal, Radhika; Sesques, Pierre; Ailawadhi, Sikander; Logue, Jennifer M.; Bräunlein, Eva; Cordas dos Santos, David M.; Freeman, Ciara L.; Alsina, Melissa; Theurich, Sebastian; Wang, Yucai; Krackhardt, Angela M.; Locke, Frederick L.; Bachy, Emmanuel; Jain, Michael D.; Lin, Yi; Subklewe, Marion (2023): The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. Journal of Hematology & Oncology, 16 (88). ISSN 1756-8722

Abstract

Background
Asthma is an inflammatory lung disease that constitutes the most common noncommunicable chronic disease in childhood. Childhood asthma shows large heterogeneity regarding onset of disease, symptoms, severity, prognosis, and response to therapy.

Main body
Evidence suggests that this variability is due to distinct pathophysiological mechanisms, which has led to an exhaustive research effort to understand and characterize these distinct entities currently designated as “endotypes.” Initially, studies focused on identifying specific groups using clinical variables yielding different “clinical phenotypes.” In addition, the identification of specific patterns based on inflammatory cell counts and cytokine data has resulted in “inflammatory endotypes.” More recently, an increasing number of molecular data from high-throughput technology (“omics” data) have allowed to investigate more complex “molecular endotypes.”

Conclusion
A better definition and comprehension of childhood asthma heterogeneity is key for improving diagnosis and treatment. This review aims at summarizing the current knowledge on this topic and discusses some limitations in their application as well as recommendations for future studies.

• Dokumententyp: Artikel (Klinikum der LMU)
• Organisationseinheit (Fakultäten): 07 Medizin > Klinikum der LMU München > Medizinische Klinik und Poliklinik III (Onkologie)
• DFG-Fachsystematik der Wissenschaftsbereiche: Lebenswissenschaften
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 452881907
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 451580403